The abstract is read at the publisher; the summary is JClub's.
FAK/SRC signaling mediates feedback activation of RAS/MAPK and AKT pathways after KRAS G12C inhibitor treatment, and FAK/SRC blockade resensitizes sotorasib-resistant cells.
- Why it matters: Adaptive signaling after KRAS pathway inhibition can promote resistance and limit monotherapy efficacy, creating a need for combinatorial strategies that both improve responses and prevent resistance.
- What they did: Using high-throughput drug screening and preclinical models, the study tested combinations and found synergy between FAK or SRC inhibitors and KRAS G12C inhibitors, including resensitization with acquired resistance to sotorasib.
- The result: In xenograft models, pharmacologic FAK blockade enhanced the antitumor activity of KRAS inhibitors, supporting FAK/SRC inhibition as a way to mitigate adaptive signaling.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.